جامعة المعرفة
المصدر المعتمد للمعلومات البحثية والمخرجات هو قاعدة بيانات سكوبس (Elsevier Scopus) مع تدقيق بيانات الباحثين من عمادة البحث العلمي.

Research outputs

المخرجات البحثية

مقالات ومراجعات وأوراق مؤتمرات وفصول كتب، مفهرسة برقم DOI ومربوطة بباحثي الجامعة.

4 مُخرَج نتائج البحث عن «Confounding»

مراجعةوصول مفتوح2026

Comparison Between High-Flow Nasal Cannula (HFNC) Therapy and Noninvasive Ventilation (NIV) in Children With Bronchiolitis-Associated Acute Respiratory Failure: A Systematic Review and Meta-Analysis

Cureus · مجلد 18 (8) · e114308-e114308

The optimal noninvasive respiratory support for infants and children with severe viral bronchiolitis remains unclear. While continuous positive airway pressure (CPAP) has traditionally been considered the gold standard, high-flow nasal cannula (HFNC) therapy is a better-tolerated alternative. This systematic review and meta-analysis aimed to evaluate the comparative efficacy and safety of HFNC versus noninvasive ventilation (NIV) in pediatric patients with bronchiolitis-associated acute respiratory failure. We searched major electronic databases through June 2026. We included randomized controlled trials (RCTs) and observational cohorts comparing HFNC with NIV (CPAP/bilevel positive airway pressure (BiPAP)). The primary outcomes were treatment failure, as defined by the individual studies, and endotracheal intubation. Data were synthesized using random-effects models, and heterogeneity was explored via subgroup analysis and meta-regression. Eleven studies (seven RCTs and four observational studies) comprising 7,574 patients were included. There was no statistically significant difference in the overall risk of treatment failure between HFNC and NIV (RR 1.99, 95% CI 0.65-6.10); however, study design was a significant moderator (p = 0.0019). Observational studies reported significantly higher failure rates with HFNC (RR 7.78), whereas RCTs showed no significant difference (RR 1.11). There were no significant differences in endotracheal intubation rates (RR 0.75, 95% CI 0.51-1.09) or pediatric intensive care unit length of stay (MD -0.16 days, 95% CI -0.79 to 0.47) between the groups. HFNC demonstrated a trend toward fewer local adverse events, such as nasal/skin trauma (RR 0.30, 95% CI 0.06-1.52), than did NIV. The certainty of evidence according to GRADE was low for all outcomes. HFNC showed no significant differences from NIV in critical clinical endpoints, including intubation rates and intensive care duration. Differences in treatment failure rates appeared to be influenced by study design, highlighting potential confounding by indication in observational data. Given its improved tolerability and trend toward reduced mucosal trauma, HFNC may represent a viable first-line noninvasive intervention for pediatric bronchiolitis.

high-flow nasal cannulanon-invasive ventilationpediatric bronchiolitisacute respiratory failure
مراجعةمفتوح (مستودع)2026

Early Versus Late Initiation of High-Efficacy Disease-Modifying Therapies in Relapsing-Remitting Multiple Sclerosis: A Systematic Review and Meta-Analysis

Annals of Middle Eastern Medicine

Background: Relapsing-remitting multiple sclerosis is a chronic immune-mediated disorder of the central nervous system associated with recurrent inflammatory activity and long-term disability accumulation. Although escalation therapy has traditionally been used, early initiation of high-efficacy disease-modifying therapies may provide stronger inflammatory control and improve long-term outcomes. Objective: This systematic review and meta-analysis aimed to compare early initiation of high-efficacy disease-modifying therapies with escalation or delayed treatment strategies in adults with relapsing-remitting multiple sclerosis. Methods: PubMed, Scopus, and Web of Science were systematically searched. Eligible studies included adults with relapsing-remitting multiple sclerosis treated with either early high-efficacy disease-modifying therapies or escalation/delayed strategies. Outcomes included annualized relapse rate, Expanded Disability Status Scale change, and delta-Expanded Disability Status Scale. Study quality was assessed using the Newcastle-Ottawa Scale, and pooled analyses were performed using random-effects models. Results: Ten observational cohort studies were included. Early initiation of high-efficacy treatment was associated with lower annualized relapse rate than escalation therapy. Disability findings remained uncertain. The pooled EDSS-change analysis was not statistically significant and showed considerable heterogeneity. Only one eligible study reported an adjusted delta-EDSS comparison; therefore, this outcome was reported narratively and was not meta-analyzed. Nonrandom treatment allocation and potential confounding by indication limit causal interpretation. Conclusion: Early initiation of high-efficacy disease-modifying therapy was associated with lower relapse activity in observational RRMS cohorts. The available disability evidence does not establish a causal advantage of either treatment strategy and requires cautious interpretation.

relapsing-remitting multiple sclerosisdisease-modifying therapyearly treatment initiationtreatment delay
مراجعةوصول مغلق20252استشهاد· Semantic Scholar

Impact of adenotonsillectomy on asthma control in children: a systematic review and meta-analysis of clinical outcomes

Journal of Asthma · مجلد 63 (1) · 1-14

Objective This study evaluated the impact of adenotonsillectomy on asthma symptoms in children by combining observational evidence with pooled analysis.Data sources We searched MEDLINE/PubMed, Cochrane Central Register of Controlled Trials, Web of Science, ProQuest, and Scopus from inception to March 17, 2025.Study selection Eligible studies assessed asthma outcomes in children undergoing adenotonsillectomy using retrospective or prospective cohort designs, case series, or database analyses. Eleven studies involving 74,204 participants were identified. Outcomes included asthma control scores (ACT/cACT), acute asthma exacerbations (AAEs), emergency department (ED) visits, oral corticosteroid use, hospitalization, inflammatory biomarkers, and atopic risk. Risk of bias was evaluated using ROBINS-I.Results Meta-analysis incorporated five studies with 52,479 participants. Adenotonsillectomy improved ACT/cACT scores by a mean of 2.5 points (95% CI:1.6–3.4; I2=0%), indicating better asthma control. A reduced risk of AAEs was observed (RD = 0.29; 95% CI:0.01–0.58), though with extreme heterogeneity (I2=100%). ED visits showed a small but significant reduction (MD=–0.01; 95% CI:0.00–0.02; I2=0%). Narrative synthesis found corticosteroid courses decreased by 23.7%, hospitalization rates fell by up to 35.8%, and patients reported improved quality of life and lower inflammatory biomarkers. However, most studies carried moderate to severe risk of bias due to confounding and selection issues.Conclusions Adenotonsillectomy may improve asthma control, reduce ED visits, and lessen medication use and hospitalization among children. Evidence regarding its effect on exacerbations remains inconsistent, and causality cannot be inferred due to reliance on observational data. Well-designed prospective controlled trials are needed to confirm effectiveness and clarify underlying mechanisms.

adenotonsillectomychildhood asthmaasthma controlacute asthma exacerbation
مراجعةوصول مفتوح20252استشهاد· Semantic Scholar

Antiplatelet Resumption After Intracerebral Hemorrhage: A Systematic Review and Meta-Analysis

Diagnostics · مجلد 15 (14) · 1780-1780

Background: Intracerebral hemorrhage management presents clinicians with a significant therapeutic challenge. Maintaining antiplatelet therapy potentially increases the risk of recurrent bleeding, while discontinuation heightens susceptibility to ischemic stroke, particularly during the critical first month after hemorrhage. In contemporary practice, physicians demonstrate considerable hesitancy regarding early antiplatelet reinitiation, complicated by the absence of clear evidence-based treatment guidelines. Aim: This meta-analysis assesses the safety of early antiplatelet resumption following ICH. Methods: We conducted a systematic review by searching Web of Science, Scopus, PubMed, and Cochrane Library from inception to April 2025. Articles were independently screened and data extracted by two reviewers who also assessed study quality. The inclusion criteria are enrollment of adults (≥18 years) with imaging-confirmed intracerebral hemorrhage surviving >24 h, comparing early vs. delayed or withheld antiplatelet therapy. Randomized trials underwent separate evaluation using Cochrane’s Risk of Bias. Statistical analysis was performed using R software (version 4.4.2), with categorical outcomes pooled as risk ratios (RRs) with 95% confidence intervals. Statistical significance was established at p < 0.05. The evidence is limited by the availability of few RCTs, variable antiplatelet regiments, male predominance, and other confounding factors. The review was registered in SFO. Results: Our meta-analysis included 10 studies (8 observational, 2 RCTs) with 5554 patients. Early antiplatelet therapy significantly reduced recurrent intracerebral hemorrhage by 46% (RR 0.54, 95% CI 0.37–0.78, p = 0.001). All-cause mortality showed a non-significant difference (RR 0.81, 95% CI 0.65–1.01, p = 0.06). No significant differences were found for ischemic stroke (RR 0.99, 95% CI 0.60–1.63, p = 0.96), major hemorrhagic events (RR 0.75, 95% CI 0.49–1.13, p = 0.17), or ischemic vascular outcomes (RR 0.71, 95% CI 0.49–1.02, p = 0.60). Conclusions: Our meta-analysis reveals that early antiplatelet therapy following intracerebral hemorrhage significantly reduces recurrent hemorrhagic events (46% reduction) without increasing major ischemic or hemorrhagic complications.

intracerebral hemorrhageantiplatelet therapyrecurrent intracerebral hemorrhageischemic stroke